Shorter treatment duration a possibility for pulmonary TB
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
Browsing: Antibiotics
Nearly three-quarters of parents who keep leftover antibiotics share them with others
A new survey has reported that nearly half of parents have kept leftover antibiotics, and of these 73% have shared the drugs with other family and non-family.
Investigational antibiotic effective against drug-resistant UTIs in Phase II trial
A Phase II trial has demonstrated that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care for treating complicated UTIs caused by multi-drug resistant bacteria.
The RESTORE-1 trial, results and real world repercussions – an interview with Keith Kaye
In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
IDWeek: Nearly half of outpatient antibiotic prescriptions written without infection diagnosis
Nearly half of prescriptions for antibiotics were written without an infection-related diagnosis, according to a study of 509,534 prescriptions reported at IDWeek today.
Paratek’s antibiotic Nuzyra™ (omadacycline) gains FDA approval
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Novartis and GARDP partner to accelerate the availability of antibiotics for children
GARDP and Novartis have announced a partnership hoping to accelerate the development and availability of generic antibiotics for children in LMICs.
Optimized arylomycins: a new class of Gram-negative antibiotics?
Researchers from Genentech have carried out optimization of the arylomycins, uncovering a molecule with potent, broad-spectrum activity against Gram-negative bacteria.
Merck’s ZERBAXA® meets primary endpoint in Phase III bacterial pneumonia study
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Four- and five-drug antibiotic combinations prove surprisingly effective
Over 8000 combinations of four of five antibiotics have been demonstrated to be more effective than previously thought, according to new research.